WithdrawnPHASE1, PHASE2NCT00085449

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Studying Acute mast cell leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alliance for Clinical Trials in Oncology
Principal Investigator
Sherif S. Farag, MD, PhD, FNP-BC
Indiana University Melvin and Bren Simon Cancer Center
Intervention
alemtuzumab(biological)
Eligibility
18-60 years · All sexes
Timeline
20062007

Study locations (24)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00085449 on ClinicalTrials.gov

Other trials for Acute mast cell leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute mast cell leukemia

← Back to all trials